Product Details
| Concentration | 0.5 mg/mL |
| Host | Mouse |
| Immunogen | DXd conjugated to keyhole limpet haemocyanin (KLH) |
| Clone Number | 1M2F3 |
| Isotype | IgG1 |
| Purification Method | Protein A |
| Specificity | Recognizes DXd and structurally similar molecules; binds DS-8201 |
| Validated Applications | ELISA |
| Buffer | 1×PBS, pH 7.4, with 0.05% BSA, 50% glycerol, 0.03% Proclin 300 |
| Storage | Ship on ice; store at 2-8°C for 1-2 weeks or -20°C for long term; avoid freeze-thaw cycles |
Product Applications
| Applications | ELISA |
| Recommended Dilution | 0.00005-1 µg/mL |
Bioactivity ELISA
The DXd conjugated Trastuzumab ELISA assay is developed by using Mouse Anti DXd Antibody, mAb (Cat:DTA0031) and Goat Anti Mouse IgG Antibody[HRP], mAb as the capture and detection antibodies.
Mouse Anti DXd Antibody, mAb (Cat:DTA0031) binds with DS-8201.
Coating antigen: DS-8201, 0.1 µg
Mouse Anti DXd Antibody, mAb (Cat:DTA0031) dilution start from 1000 ng/mL.
DXd is a derivative of exatecan (DX8951f), a compound with increased activity and improved solubility compared to CPT, and described not to be an ABCC2 or ABCG1 substrate. DXd was used in several proprietary ADC programs, such as DS-8201a (Enhertu), U3-1402 and DS-6157a, conjugated at DAR8 and DS-1062a and DS-7300a conjugated at lower DAR (4) to limit their toxicity, that are either approved by the FDA (DS-8201a) or currently under clinical evaluation. Although the DXd payload presented lower passive membrane permeability than exatecan mesylate, it was found to be less myelotoxic and was therefore also selected for its improved safety profile.
The anti-payload antibody is a useful reagent in ADC research by quantifying and monitoring drug levels or accumulations in tumor tissue, and more. It can be used in PK, PD analysis and ELISA.
